Global In Vitro Diagnostic Products to Reach $61.8 Billion in 2015

The US will remain the largest market for IVD products, absorbing nearly 36 percent of global demand in 2015, or $22 billion.  The country will maintain this leading position because of aging demographic patterns, a high health care spending intensity, the favorable receptiveness of medical providers to new reagents and instruments, and overall trends promoting the use of patient tests to detect diseases in early, more treatable stages.  Western Europe, Japan and other developed economies will also continue to provide a high and diverse volume of IVD testing.  However, tighter insurance-imposed cost controls will keep per capita demand for related reagents and instruments below US levels.

Developing world demand for IVD products will rise much faster than developed world demand as countries upgrade and expand health care systems.  These improvements will boost the volume of patient tests, especially in China and other emerging economies.  Nonetheless, the ongoing constraints on health care spending and less advanced nature of medical delivery systems in most developing countries will keep IVD product demand largely in low cost reagents and instruments for basic health screening.

The Freedonia Group is a leading international business research company, founded in 1985, that publishes more than 100 industry research studies annually. This industry analysis provides an unbiased outlook and a reliable assessment of an industry and includes product segmentation and demand forecasts, industry trends, demand history, threats and opportunities, competitive strategies, market share determinations and company profiles.